Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Medtronic
Cipla
US Department of Justice
Citi
Healthtrust
Colorcon
AstraZeneca
Merck

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SACUBITRIL; VALSARTAN

« Back to Dashboard

Clinical Trials for Sacubitril; Valsartan

Trial ID Title Status Sponsor Phase Summary
NCT02554890 comParIson Of Sacubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode Recruiting Novartis Pharmaceuticals Phase 4 The purpose of this study is to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
NCT02636283 Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Not yet recruiting American Heart Association Phase 2 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Not yet recruiting University of Minnesota - Clinical and Translational Science Institute Phase 2 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02682719 ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation Recruiting Novartis Ireland Ltd Phase 2 The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or diabetes or other risk factors for developing heart failure (elevated levels of natriuretic peptide and elevated left atrial volume index). Patients will be randomized to receive LCZ696 or valsartan (and matching placebo) for 18 months to assess the impact on left ventricular diastolic function.
NCT02682719 ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation Recruiting The Heartbeat Trust Phase 2 The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or diabetes or other risk factors for developing heart failure (elevated levels of natriuretic peptide and elevated left atrial volume index). Patients will be randomized to receive LCZ696 or valsartan (and matching placebo) for 18 months to assess the impact on left ventricular diastolic function.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Sacubitril; Valsartan

Condition Name

Condition Name for Sacubitril; Valsartan
Intervention Trials
Heart Failure 8
Congestive Heart Failure 2
Hypertension 2
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sacubitril; Valsartan
Intervention Trials
Heart Failure 20
Apnea 1
Prediabetic State 1
Peripheral Vascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sacubitril; Valsartan

Trials by Country

Trials by Country for Sacubitril; Valsartan
Location Trials
United States 25
Canada 8
Ireland 1
Germany 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sacubitril; Valsartan
Location Trials
Texas 3
Minnesota 2
Illinois 2
Pennsylvania 2
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sacubitril; Valsartan

Clinical Trial Phase

Clinical Trial Phase for Sacubitril; Valsartan
Clinical Trial Phase Trials
Phase 4 13
Phase 3 3
Phase 2 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sacubitril; Valsartan
Clinical Trial Phase Trials
Recruiting 12
Not yet recruiting 10
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sacubitril; Valsartan

Sponsor Name

Sponsor Name for Sacubitril; Valsartan
Sponsor Trials
Novartis Pharmaceuticals 9
Brigham and Women's Hospital 2
DLR German Aerospace Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sacubitril; Valsartan
Sponsor Trials
Other 20
Industry 11
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Argus Health
McKesson
Medtronic
Mallinckrodt
Julphar
Cipla
Fish and Richardson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.